PureTech launches Vor BioPharma

PureTech Health plc (LSE:PRTC) launched Vor BioPharma Inc., an immuno-oncology company focused on chimeric antigen receptor (CAR) T cell therapies. PureTech said the newco licensed IP from the laboratory of Siddhartha Mukherjee, an assistant professor of medicine at Columbia University.

PureTech is Vor's sole investor, and describes the company as a wholly-owned subsidiary. ...